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1199opinion, to overcome the downsides associated with
technological advances as they do not directly
address all potential issues of technique, judgment,
and decision making in the individual patient.
According to the Accreditation Council for Graduate
Medical Education, the minimal requirement for
interventional training today is to perform 250 coro-
nary procedures per year as the primary operator.
I personally doubt whether this number is sufﬁcient,
given all the nuances in treating sick, complex pa-
tients, particularly in the acute setting.
Even if minimal numbers were increased (there is
not one number that ﬁts all), it is essential that the
young interventionalist in training uses all available
tools. I believe that this should be mandatory. These
would include training with hands-on simulation
programs and review and live demonstration semi-
nars, all of which are given by interventional societies
such as the Society for Cardiac Angiography and
Intervention. Most importantly, all fellows ﬁnishing
training should seek the help of a seasoned, experi-
enced interventionalist whenever feasible who
can provide input in all cases for an indeﬁnite period
of time. Those of us with this experience should
make ourselves available. Finally, all of us should
strive to review, whenever possible, all complex cases,
particularly if not emergent, before the percuta-
neous coronary intervention procedure with other
interventionalists and, when appropriate, cardiac
surgeons.
Interventional cardiology is an art as well as a
science. In other disciplines, apprenticeships last for
several years. Although it is not practical to spend
additional years in training, learning is a lifelong
journey. I believe that we owe this to the patient and
to our profession. If nothing else, I hope that this
point of view will generate discussion among our
colleagues.*John A. Ambrose, MD
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Prediction of
Hyperglycemia at
Coronary AngiographyPeriprocedural hyperglycemia is a potentially re-
versible cause of poor outcomes in patients with
diabetes mellitus (DM) undergoing percutaneous
coronary intervention (PCI) (1,2). However, simple
preventive strategies such as continuing long-acting
glucose-lowering medications are not routinely
implemented due to concern for hypoglycemia (3).
We recently demonstrated the efﬁcacy of continuing
rather than holding long-acting glucose-lowering
medications in patients with DM undergoing coronary
angiography with possible PCI (4). In this study, we
sought to develop a risk score to predict hyperglyce-
mia at the time of coronary angiography in patients
with DM to help target a high-risk group of patients
for whom the beneﬁts of treatment may outweigh the
risks of hypoglycemia.
In the periprocedural glycemic control trial at the
Manhattan Veterans Affairs Hospital, patients with
DM were randomized to continue or hold long-acting
glucose-lowering medications before coronary angi-
ography (4). The hold group (n ¼ 86) serves as the
development cohort, and details regarding this cohort
were previously described (4).
Patients undergoing PCI between November 2010
and February 2012 participated in a prospective reg-
istry at the New York University Langone Medical
Center. Those with pharmacologically treated DM and
recorded blood glucose at the time of the procedure
(n ¼ 168) served as the validation cohort. A nurse
educator provided telephone instructions to hold
glucose-lowering medications before the procedure
during this time per routine care. Although variables
of interest in the validation cohort were prospectively
collected, fasting time and periprocedural glucose
were collected by retrospective review of the elec-
tronic procedural charts.
TABLE 1 Independent Predictors of Periprocedural Hyperglycemia in the
Development Cohort
Odds Ratio (log) SE p Value Assigned Integer Score
Insulin or sulfonylurea 1.24 0.66 0.06 3
Insulin and sulfonylurea 2.58 1.05 0.01 5
Hemoglobin A1c $6.5% 2.00 0.71 0.02 4
Random glucose $120 mg/dl 0.93 0.85 0.19 2
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1200Predictors of periprocedural hyperglycemia,
deﬁned as glucose $140 mg/dl, were determined in
the development cohort using multivariable logistic
regression. Each independent predictor was assigned
a weighted integer based on an estimate of the log
odds ratio. Summation of integers determined risk
score. Trends in proportions of hyperglycemia across
tertiles of risk score were examined using the Cochran
Armitage trend test. Proportions of hyperglycemia in
the development cohort versus validation cohort
in each tertile risk score were examined using a
2-sample test for equality of proportions with con-
tinuity correction.
The proportion of patients with periprocedural
hyperglycemia in the development cohort was
47.7% (n ¼ 41). Although the patients in the devel-
opment cohort were all men and 73.3% of white race
with a median age of 66 years, patients in the vali-
dation cohort were 68.5% men and 46.4% of white
race with a median age of 67 years. A little less than
half of patients were taking sulfonylurea agents
(45.3% development cohort, 40.5% validation
cohort) and long-acting insulin (40.7% development
cohort, 33.3% validation cohort), whereas more
than half were receiving metformin therapy (61.6%
development cohort, 67.3% validation cohort). A
minority of patients was on thiazoladinediones
(4.7% development cohort, 14.9% validation cohort)
or sitagliptin (0% development cohort, 29.2% vali-
dation cohort). The median (interquartile range)
random glucose and hemoglobin A1c was 145.5 mg/dl
(120 to 186.3 mg/dl) and 7.3% (6.8% to 8%) in the
development cohort, respectively, and 158.8 mg/dl
(109 to 184.5 mg/dl) and 7.6% (6.5% to 8.4%) in the
validation cohort, respectively. Finally, the median
(interquartile range) fasting time was 17.3 h (14.4 h
to 19.3 h) in the development cohort and 10.6 h (8.3
h to 12.8 h) in the validation cohort.
Independent predictors of hyperglycemia in the
development cohort, with assigned integer, are shown
in Table 1. Increasing risk score was associated
with greater proportion of patients with hyperglyce-
mia (development cohort risk score <6: 11%; score 6
to 9: 31.25%; score $9: 68%; p < 0.001; validation
cohort risk score <6: 24.44%; score 6 to 10:44.68%; score $10; 73.24%; p < 0.001). There was no
signiﬁcant difference between the proportion of
patients with hyperglycemia in the development and
validation cohorts in each risk tertile (ﬁrst, p ¼ 0.35;
second, p ¼ 0.52; third, p ¼ 0.67). The risk score
model displayed good discriminative power in the
development cohort (C-statistic ¼ 0.75; 95% conﬁ-
dence interval: 0.66 to 0.85) and the validation cohort
(C-statistic ¼ 0.74; 95% conﬁdence interval: 0.66 to
0.81) with a similar effect in both cohorts (interaction
p value ¼ 0.23).
Hyperglycemia contributes to endothelial dys-
function and inﬂammation (5). Acute hyperglycemia
increases platelet activation despite the use of anti-
platelet agents, enhances thrombin formation, and
impairs ﬁbrinolysis (6). Among patients with DM
undergoing PCI, periprocedural hyperglycemia is
associated with target vessel revascularization,
myocardial injury, and contrast-induced renal injury,
making periprocedural hyperglycemia an important
risk factor to investigate further (2). We have shown
that continuing oral glucose-lowering drugs in
patients undergoing coronary angiography with
possible PCI reduces the incidence of hyperglycemia
and normalizes platelet function (4).
Event rates are too small to identify predictors of
hypoglycemia in patients with DM undergoing coro-
nary angiography (4). However, the risk of hypergly-
cemia in this population can be evaluated using
readily available clinical data and may be used to
guide the intensity of periprocedural glycemic control
as well as deﬁne a high-risk population that may be
appropriate for future studies of periprocedural
glycemic control.
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